Prana raises cash and expectations
Wednesday, 12 September, 2007
Prana Biotechnology has announced a new private share offer to raise up to $10 million to further fund the development of its lead compound PBT2, currently in a Phase IIa trial in patients with Alzheimer's disease.
This trial, scheduled for completion in December, is designed to advance the commercialisation of Prana's programs to develop novel treatments for neurodegenerative disorders.
The Phase IIa trial of PBT2 is a double-blind, placebo-controlled safety and tolerability study in patients with Alzheimer's disease.
The trial is well advanced, with over 70 per cent of study patients dosed, and almost half of the target 80 patients have already completed the trial.
"Given this progress, we are particularly pleased with the positive safety and tolerability demonstrated by PBT2 to date," Prana's CEO, Geoffrey Kempler, said.
"We are on track to complete the trial by the end of the year and report results in the first quarter of 2008."
The placement is subject to shareholder approval at a meeting in October 15.
Source: Prana Biotechnology
Liquid fat treatment provides hope for rare childhood disease
A liquid fat supplement, triheptanoin, can reverse mitochondrial dysfunction and cell death in...
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
